{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T06:04:13Z","timestamp":1787724253784,"version":"build-2784847793"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T00:00:00Z","timestamp":1620000000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T00:00:00Z","timestamp":1620000000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Boehringer Ingelheim Pharma GmbH & Co KG"},{"name":"Boehringer Ingelheim Pharma GmbH & Co KG"},{"name":"Boehringer Ingelheim Pharma GmbH & Co KG"},{"name":"Boehringer Ingelheim Pharma GmbH & Co KG"},{"name":"Boehringer Ingelheim Pharma GmbH & Co KG"},{"name":"Boehringer Ingelheim Pharma GmbH & Co KG"},{"name":"Boehringer Ingelheim Pharma GmbH & Co KG"},{"name":"Boehringer Ingelheim Pharma GmbH & Co KG"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neuropsychopharmacol."],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>BI 409306, a phosphodiesterase-9 inhibitor under development for treatment of schizophrenia and attenuated psychosis syndrome (APS), promotes synaptic plasticity and cognition. Here,\u00a0we explored the effects of BI 409306 treatment in the polyriboinosinic-polyribocytidilic acid (poly[I:C])-based mouse model of maternal immune activation (MIA), which is relevant to schizophrenia and APS. In Study 1, adult offspring received BI 409306 0.2, 0.5, or 1\u2009mg\/kg or vehicle to establish an active dose. In Study 2, adult offspring received BI 409306 1\u2009mg\/kg and\/or risperidone 0.025\u2009mg\/kg, risperidone 0.05\u2009mg\/kg, or vehicle, to evaluate BI 409306 as add-on to standard therapy for schizophrenia. In Study 3, offspring received BI 409306 1\u2009mg\/kg during adolescence only, or continually into adulthood to evaluate preventive effects of BI 409306. We found that BI 409306 significantly mitigated MIA-induced social interaction deficits and amphetamine-induced hyperlocomotion, but not prepulse inhibition impairments, in a dose-dependent manner (Study 1). Furthermore, BI 409306 1\u2009mg\/kg alone or in combination with risperidone 0.025\u2009mg\/kg significantly reversed social interaction deficits and attenuated amphetamine-induced hyperlocomotion in MIA offspring (Study 2). Finally, we revealed that BI 409306 1\u2009mg\/kg treatment restricted to adolescence prevented adult deficits in social interaction, whereas continued treatment into adulthood also significantly reduced amphetamine-induced hyperlocomotion (Study 3). Taken together, our findings suggest that symptomatic treatment with BI 409306 can restore social interaction deficits and dopaminergic dysfunctions in a MIA model of neurodevelopmental disruption, lending preclinical support to current clinical trials of BI 409306 in patients with schizophrenia. Moreover, BI 409306 given during adolescence has preventive effects on adult social interaction deficits in this model, supporting its use in people with APS.<\/jats:p>","DOI":"10.1038\/s41386-021-01016-3","type":"journal-article","created":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T15:03:29Z","timestamp":1620054209000},"page":"1526-1534","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Symptomatic and preventive effects of the novel phosphodiesterase-9 inhibitor BI 409306 in an immune-mediated model of neurodevelopmental disorders"],"prefix":"10.1038","volume":"46","author":[{"given":"Joseph","family":"Scarborough","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Mattei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia","family":"Dorner-Ciossek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Sand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Arban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger","family":"Rosenbrock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8313-3348","authenticated-orcid":false,"given":"Juliet","family":"Richetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7244-0345","authenticated-orcid":false,"given":"Urs","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,3]]},"reference":[{"key":"1016_CR1","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.pbb.2011.03.023","volume":"100","author":"CH Lin","year":"2012","unstructured":"Lin CH, Lane HY, Tsai GE. Glutamate signaling in the pathophysiology and therapy of schizophrenia. Pharmacol Biochem Behav. 2012;100:665\u201377.","journal-title":"Pharmacol Biochem Behav"},{"key":"1016_CR2","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.schres.2014.12.026","volume":"167","author":"SM Cohen","year":"2015","unstructured":"Cohen SM, Tsien RW, Goff DC, Halassa MM. The impact of NMDA receptor hypofunction on GABAergic neurons in the pathophysiology of schizophrenia. Schizophr Res. 2015;167:98\u2013107.","journal-title":"Schizophr Res"},{"key":"1016_CR3","doi-asserted-by":"publisher","unstructured":"Snyder MA, Gao WJ. NMDA receptor hypofunction for schizophrenia revisited: perspectives from epigenetic mechanisms. Schizophr Res. 2019. https:\/\/doi.org\/10.1016\/j.schres.2019.03.010:60-70. https:\/\/doi.org\/10.1016\/j.schres.2019.03.010.","DOI":"10.1016\/j.schres.2019.03.010:60-70 10.1016\/j.schres.2019.03.010"},{"key":"1016_CR4","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s00213-008-1273-x","volume":"202","author":"OA Reneerkens","year":"2009","unstructured":"Reneerkens OA, Rutten K, Steinbusch HW, Blokland A, Prickaerts J. Selective phosphodiesterase inhibitors: a promising target for cognition enhancement. Psychopharmacology. 2009;202:419\u201343.","journal-title":"Psychopharmacology"},{"key":"1016_CR5","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/978-3-319-58811-7_9","volume":"17","author":"C Dorner-Ciossek","year":"2017","unstructured":"Dorner-Ciossek C, Kroker KS, Rosenbrock H. Role of PDE9 in Cognition. Adv Neurobiol. 2017;17:231\u201354.","journal-title":"Adv Neurobiol"},{"key":"1016_CR6","doi-asserted-by":"publisher","first-page":"15559","DOI":"10.1074\/jbc.273.25.15559","volume":"273","author":"DA Fisher","year":"1998","unstructured":"Fisher DA, Smith JF, Pillar JS, St. Denis SH, Cheng JB. Isolation and characterization of PDE9A, a novel human cGMP-specific phosphodiesterase. J Biol Chem. 1998;273:15559\u201364.","journal-title":"J Biol Chem"},{"key":"1016_CR7","doi-asserted-by":"publisher","unstructured":"Rosenbrock H, Giovannini R, Koros E, Runge F, Fuchs H, Marti A, et al. The novel phosphodiesterase 9A inhibitor BI 409306 increases cyclic guanosine monophosphate levels in the brain, promotes synaptic plasticity and enhances memory function in rodents. J Pharmacol Exp Ther. 2019. https:\/\/doi.org\/10.1124\/jpet.119.260059:633-41. https:\/\/doi.org\/10.1124\/jpet.119.260059.","DOI":"10.1124\/jpet.119.260059:633-41 10.1124\/jpet.119.260059"},{"key":"1016_CR8","doi-asserted-by":"publisher","unstructured":"Boland K, Moschetti V, Dansirikul C, Pichereau S, Gheyle L, Runge F, et al. A phase I, randomized, proof-of-clinical-mechanism study assessing the pharmacokinetics and pharmacodynamics of the oral PDE9A inhibitor BI 409306 in healthy male volunteers. Hum Psychopharmacol. 2017;32. https:\/\/doi.org\/10.1002\/hup.2569.","DOI":"10.1002\/hup.2569"},{"key":"1016_CR9","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.biopsych.2013.07.011","volume":"75","author":"U Meyer","year":"2014","unstructured":"Meyer U. Prenatal poly(i:C) exposure and other developmental immune activation models in rodent systems. Biol Psychiatry. 2014;75:307\u201315.","journal-title":"Biol Psychiatry"},{"key":"1016_CR10","doi-asserted-by":"publisher","first-page":"S421","DOI":"10.1016\/j.biopsych.2018.02.1082","volume":"83","author":"M Sand","year":"2018","unstructured":"Sand M, Brown D, Walling D, Daniels K, McGinniss J. S190. Prevention of relapse in schizophrenia: a phase II study evaluating efficacy, safety, and tolerability of oral BI 409306. Biol Psychiatry 2018;83:S421.","journal-title":"Biol Psychiatry"},{"key":"1016_CR11","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1176\/appi.ajp.2018.17121311","volume":"175","author":"AS Brown","year":"2018","unstructured":"Brown AS, Meyer U. Maternal immune activation and neuropsychiatric illness: a translational research perspective. Am J Psychiatry 2018;175:1073\u201383.","journal-title":"Am J Psychiatry"},{"key":"1016_CR12","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1016\/j.neuropharm.2011.01.009","volume":"62","author":"U Meyer","year":"2012","unstructured":"Meyer U, Feldon J. To poly(I:C) or not to poly(I:C): advancing preclinical schizophrenia research through the use of prenatal immune activation models. Neuropharmacology. 2012;62:1308\u201321.","journal-title":"Neuropharmacology"},{"key":"1016_CR13","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1523\/JNEUROSCI.5408-09.2010","volume":"30","author":"S Vuillermot","year":"2010","unstructured":"Vuillermot S, Weber L, Feldon J, Meyer U. A longitudinal examination of the neurodevelopmental impact of prenatal immune activation in mice reveals primary defects in dopaminergic development relevant to schizophrenia. J Neurosci. 2010;30:1270\u201387.","journal-title":"J Neurosci"},{"key":"1016_CR14","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.biopsych.2005.07.031","volume":"59","author":"K Ozawa","year":"2006","unstructured":"Ozawa K, Hashimoto K, Kishimoto T, Shimizu E, Ishikura H, Iyo M. Immune activation during pregnancy in mice leads to dopaminergic hyperfunction and cognitive impairment in the offspring: a neurodevelopmental animal model of schizophrenia. Biol Psychiatry 2006;59:546\u201354.","journal-title":"Biol Psychiatry"},{"key":"1016_CR15","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1038\/sj.npp.1300248","volume":"28","author":"L Zuckerman","year":"2003","unstructured":"Zuckerman L, Rehavi M, Nachman R, Weiner I. Immune activation during pregnancy in rats leads to a postpubertal emergence of disrupted latent inhibition, dopaminergic hyperfunction, and altered limbic morphology in the offspring: a novel neurodevelopmental model of schizophrenia. Neuropsychopharmacology. 2003;28:1778\u201389.","journal-title":"Neuropsychopharmacology"},{"key":"1016_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/1756-6606-5-22","volume":"5","author":"CM Forrest","year":"2012","unstructured":"Forrest CM, Khalil OS, Pisar M, Smith RA, Darlington LG, Stone TW. Prenatal activation of Toll-like receptors-3 by administration of the viral mimetic poly(I:C) changes synaptic proteins, N-methyl-D-aspartate receptors and neurogenesis markers in offspring. Mol Brain. 2012;5:22.","journal-title":"Mol Brain"},{"key":"1016_CR17","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3389\/fpsyt.2017.00077","volume":"8","author":"T Rahman","year":"2017","unstructured":"Rahman T, Zavitsanou K, Purves-Tyson T, Harms LR, Meehan C, Schall U, et al. Effects of immune activation during early or late gestation on N-methyl-d-aspartate receptor measures in adult rat offspring. Front Psychiatry. 2017;8:77.","journal-title":"Front Psychiatry"},{"key":"1016_CR18","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.bbi.2007.09.012","volume":"22","author":"U Meyer","year":"2008","unstructured":"Meyer U, Nyffeler M, Yee BK, Knuesel I, Feldon J. Adult brain and behavioral pathological markers of prenatal immune challenge during early\/middle and late fetal development in mice. Brain Behav Immun. 2008;22:469\u201386.","journal-title":"Brain Behav Immun"},{"key":"1016_CR19","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.neulet.2011.06.011","volume":"500","author":"NL Roenker","year":"2011","unstructured":"Roenker NL, Gudelsky G, Ahlbrand R, Bronson SL, Kern JR, Waterman H, et al. Effect of paliperidone and risperidone on extracellular glutamate in the prefrontal cortex of rats exposed to prenatal immune activation or MK-801. Neurosci Lett. 2011;500:167\u201371.","journal-title":"Neurosci Lett"},{"key":"1016_CR20","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.jpsychires.2004.08.008","volume":"39","author":"L Zuckerman","year":"2005","unstructured":"Zuckerman L, Weiner I. Maternal immune activation leads to behavioral and pharmacological changes in the adult offspring. J Psychiatr Res. 2005;39:311\u201323.","journal-title":"J Psychiatr Res"},{"key":"1016_CR21","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1038\/sj.npp.1301413","volume":"33","author":"U Meyer","year":"2008","unstructured":"Meyer U, Nyffeler M, Schwendener S, Knuesel I, Yee BK, Feldon J. Relative prenatal and postnatal maternal contributions to schizophrenia-related neurochemical dysfunction after in utero immune challenge. Neuropsychopharmacology. 2008;33:441\u201356.","journal-title":"Neuropsychopharmacology"},{"key":"1016_CR22","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1017\/S109285291900124X","volume":"24","author":"A Krogmann","year":"2019","unstructured":"Krogmann A, Peters L, von Hardenberg L, B\u00f6deker K, N\u00f6hles VB, Correll CU. Keeping up with the therapeutic advances in schizophrenia: a review of novel and emerging pharmacological entities. CNS Spectr. 2019;24:38\u201369.","journal-title":"CNS Spectr"},{"key":"1016_CR23","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.neubiorev.2004.10.012","volume":"29","author":"U Meyer","year":"2005","unstructured":"Meyer U, Feldon J, Schedlowski M, Yee BK. Towards an immuno-precipitated neurodevelopmental animal model of schizophrenia. Neurosci Biobehav Rev. 2005;29:913\u201347.","journal-title":"Neurosci Biobehav Rev"},{"key":"1016_CR24","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.bbi.2019.04.019","volume":"80","author":"FS Mueller","year":"2019","unstructured":"Mueller FS, Richetto J, Hayes LN, Zambon A, Pollak DD, Sawa A, et al. Influence of poly(I:C) variability on thermoregulation, immune responses and pregnancy outcomes in mouse models of maternal immune activation. Brain Behav Immun. 2019;80:406\u201318.","journal-title":"Brain Behav Immun"},{"key":"1016_CR25","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.bbi.2020.04.015","volume":"88","author":"J Scarborough","year":"2020","unstructured":"Scarborough J, Mueller F, Arban R, Dorner-Ciossek C, Weber-Stadlbauer U, Rosenbrock H, et al. Preclinical validation of the micropipette-guided drug administration (MDA) method in the maternal immune activation model of neurodevelopmental disorders. Brain Behav Immun. 2020;88:461\u201370.","journal-title":"Brain Behav Immun"},{"key":"1016_CR26","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/s41380-020-00952-8","volume":"26","author":"FS Mueller","year":"2021","unstructured":"Mueller FS, Scarborough J, Schalbetter SM, Richetto J, Kim E, Couch A, et al. Behavioral, neuroanatomical, and molecular correlates of resilience and susceptibility to maternal immune activation. Mol Psychiatry. 2021;26:396\u2013410.","journal-title":"Mol Psychiatry"},{"key":"1016_CR27","doi-asserted-by":"publisher","first-page":"pyu055","DOI":"10.1093\/ijnp\/pyu055","volume":"18","author":"J Richetto","year":"2015","unstructured":"Richetto J, Labouesse MA, Poe MM, Cook JM, Grace AA, Riva MA, et al. Behavioral effects of the benzodiazepine-positive allosteric modulator SH-053-2\u2019F-S-CH(3) in an immune-mediated neurodevelopmental disruption model. Int J Neuropsychopharmacol. 2015;18:pyu055.","journal-title":"Int J Neuropsychopharmacol"},{"key":"1016_CR28","doi-asserted-by":"publisher","first-page":"e12523","DOI":"10.1111\/gbb.12523","volume":"18","author":"J Scarborough","year":"2019","unstructured":"Scarborough J, Mueller F, Weber-Stadlbauer U, Richetto J, Meyer U. Dependency of prepulse inhibition deficits on baseline startle reactivity in a mouse model of the human 22q11.2 microdeletion syndrome. Genes Brain Behav. 2019;18:e12523.","journal-title":"Genes Brain Behav"},{"key":"1016_CR29","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s40120-017-0085-5","volume":"7","author":"D Brown","year":"2018","unstructured":"Brown D, Daniels K, Pichereau S, Sand M. A phase IC study evaluating the safety, tolerability, pharmacokinetics, and cognitive outcomes of BI 409306 in patients with mild-to-moderate schizophrenia. Neurol Ther. 2018;7:129\u201339.","journal-title":"Neurol Ther"},{"key":"1016_CR30","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/mp.2016.41","volume":"22","author":"U Weber-Stadlbauer","year":"2017","unstructured":"Weber-Stadlbauer U, Richetto J, Labouesse MA, Bohacek J, Mansuy IM, Meyer U. Transgenerational transmission and modification of pathological traits induced by prenatal immune activation. Mol Psychiatry. 2017;22:102\u201312.","journal-title":"Mol Psychiatry"},{"key":"1016_CR31","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1038\/npp.2010.129","volume":"35","author":"BK Bitanihirwe","year":"2010","unstructured":"Bitanihirwe BK, Peleg-Raibstein D, Mouttet F, Feldon J, Meyer U. Late prenatal immune activation in mice leads to behavioral and neurochemical abnormalities relevant to the negative symptoms of schizophrenia. Neuropsychopharmacology. 2010;35:2462\u201378.","journal-title":"Neuropsychopharmacology"},{"key":"1016_CR32","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1093\/schbul\/sbn131","volume":"36","author":"U Meyer","year":"2010","unstructured":"Meyer U, Spoerri E, Yee BK, Schwarz MJ, Feldon J. Evaluating early preventive antipsychotic and antidepressant drug treatment in an infection-based neurodevelopmental mouse model of schizophrenia. Schizophr Bull. 2010;36:607\u201323.","journal-title":"Schizophr Bull"},{"key":"1016_CR33","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1124\/jpet.111.191353","volume":"341","author":"RJ Kleiman","year":"2012","unstructured":"Kleiman RJ, Chapin DS, Christoffersen C, Freeman J, Fonseca KR, Geoghegan KF, et al. Phosphodiesterase 9A regulates central cGMP and modulates responses to cholinergic and monoaminergic perturbation in vivo. J Pharm Exp Ther. 2012;341:396\u2013409.","journal-title":"J Pharm Exp Ther"},{"key":"1016_CR34","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s002130100763","volume":"156","author":"AM Ouagazzal","year":"2001","unstructured":"Ouagazzal AM, Jenck F, Moreau JL. Drug-induced potentiation of prepulse inhibition of acoustic startle reflex in mice: a model for detecting antipsychotic activity? Psychopharmacology. 2001;156:273\u201383.","journal-title":"Psychopharmacology"},{"key":"1016_CR35","doi-asserted-by":"publisher","first-page":"S216","DOI":"10.1093\/schbul\/sbx022.014","volume":"43","author":"R Keefe","year":"2017","unstructured":"Keefe R, Woods S, Cannon T, Ruhrmann S, Mathalon D, McGuire P, et al. Early intervention in attenuated psychosis syndrome: a phase II study evaluating efficacy, safety, and tolerability of oral BI 409306. Schizophr Bull. 2017;43:S216\u20137.","journal-title":"Schizophr Bull"},{"key":"1016_CR36","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/j.neuron.2015.04.022","volume":"86","author":"AJ Pocklington","year":"2015","unstructured":"Pocklington AJ, Rees E, Walters JT, Han J, Kavanagh DH, Chambert KD, et al. Novel findings from CNVs implicate inhibitory and excitatory signaling complexes in schizophrenia. Neuron. 2015;86:1203\u201314.","journal-title":"Neuron"},{"key":"1016_CR37","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/npp.2014.95","volume":"40","author":"MJ Schmidt","year":"2015","unstructured":"Schmidt MJ, Mirnics K. Neurodevelopment, GABA system dysfunction, and schizophrenia. Neuropsychopharmacology. 2015;40:190\u2013206.","journal-title":"Neuropsychopharmacology"},{"key":"1016_CR38","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.tins.2016.04.010","volume":"39","author":"A Caballero","year":"2016","unstructured":"Caballero A, Tseng KY. GABAergic function as a limiting factor for prefrontal maturation during adolescence. Trends Neurosci. 2016;39:441\u20138.","journal-title":"Trends Neurosci"},{"key":"1016_CR39","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/mp.2014.66","volume":"20","author":"RS Kahn","year":"2015","unstructured":"Kahn RS, Sommer IE. The neurobiology and treatment of first-episode schizophrenia. Mol Psychiatry. 2015;20:84\u201397.","journal-title":"Mol Psychiatry"},{"key":"1016_CR40","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.pneurobio.2015.09.010","volume":"134","author":"T Sakurai","year":"2015","unstructured":"Sakurai T, Gamo NJ, Hikida T, Kim SH, Murai T, Tomoda T, et al. Converging models of schizophrenia-Network alterations of prefrontal cortex underlying cognitive impairments. Prog Neurobiol. 2015;134:178\u2013201.","journal-title":"Prog Neurobiol"},{"key":"1016_CR41","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1093\/schbul\/sbs195","volume":"40","author":"J Richetto","year":"2014","unstructured":"Richetto J, Calabrese F, Riva MA, Meyer U. Prenatal immune activation induces maturation-dependent alterations in the prefrontal GABAergic transcriptome. Schizophr Bull. 2014;40:351\u201361.","journal-title":"Schizophr Bull"},{"key":"1016_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2015.115","volume":"5","author":"LD Selemon","year":"2015","unstructured":"Selemon LD, Zecevic N. Schizophrenia: a tale of two critical periods for prefrontal cortical development. Transl Psychiatry. 2015;5:e623.","journal-title":"Transl Psychiatry"},{"key":"1016_CR43","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/s41386-018-0185-7","volume":"44","author":"AC Kentner","year":"2019","unstructured":"Kentner AC, Bilbo SD, Brown AS, Hsiao EY, McAllister AK, Meyer U, et al. Maternal immune activation: reporting guidelines to improve the rigor, reproducibility, and transparency of the model. Neuropsychopharmacology. 2019;44:245\u201358.","journal-title":"Neuropsychopharmacology"},{"key":"1016_CR44","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.cobeha.2019.02.006","volume":"28","author":"U Weber-Stadlbauer","year":"2019","unstructured":"Weber-Stadlbauer U, Meyer U. Challenges and opportunities of a-priori and a-posteriori variability in maternal immune activation models. Curr Opin Behav Sci. 2019;28:119\u201328.","journal-title":"Curr Opin Behav Sci"},{"key":"1016_CR45","doi-asserted-by":"crossref","unstructured":"Peleg-Raibstein D, Feldon J, Meyer U. Behavioral animal models of antipsychotic drug actions. In: Gross G., Geyer MA, editors. Current antipsychotics. Handbook of experimental pharmacology, vol 212. Berlin, Heidelberg: Springer; 2012. p. 361\u2013406.","DOI":"10.1007\/978-3-642-25761-2_14"}],"container-title":["Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41386-021-01016-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-021-01016-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-021-01016-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T08:07:01Z","timestamp":1675238821000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41386-021-01016-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,3]]},"references-count":45,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["1016"],"URL":"https:\/\/doi.org\/10.1038\/s41386-021-01016-3","relation":{},"ISSN":["0893-133X","1740-634X"],"issn-type":[{"value":"0893-133X","type":"print"},{"value":"1740-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,3]]},"assertion":[{"value":"19 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}